Stefania Brotini1. 1. Dr. Brotini is with the Movement Disorder Center, Department of Neurology, San Giuseppe Hospital in Empoli, Florence, Italy.
Abstract
BACKGROUND: Camptocormia is a complication in which the spine bends forward while walking or standing. This axial postural deformity is common in Parkinson's disease (PD), with prevalence ranging from 3 to 18 percent; it is generally associated with a more severe disease and longer duration of symptoms. Camptocormia in PD typically responds poorly to levodopa. Other treatment options are limited and are often not effective. CASE PRESENTATION: We describe an unusual case of PD presenting with camptocormia that only emerged during the "off" state of PD. The patient was treated with classical dopaminergic anti-Parkinson's therapy plus a new formulation of palmitoylethanolamide co-ultramicronized with luteolin (Lut) termed um-PEALut. We observed that the addition of um-PEALut to acute treatment with carbidopa/levodopa resulted in improved dyskinesia and reduced camptocormia. The patient continued treatment for four months, resulting in a complete resolution of leg and trunk dyskinesia and a marked reduction in the onset of camptocormia during the "off" states. CONCLUSION: um-PEALut shows potential as an efficacious adjuvant therapy for patients with PD receiving carbidopa/levodopa to treat both dyskinesia and camptocormia in acute and chronic fashion.
BACKGROUND: Camptocormia is a complication in which the spine bends forward while walking or standing. This axial postural deformity is common in Parkinson's disease (PD), with prevalence ranging from 3 to 18 percent; it is generally associated with a more severe disease and longer duration of symptoms. Camptocormia in PD typically responds poorly to levodopa. Other treatment options are limited and are often not effective. CASE PRESENTATION: We describe an unusual case of PD presenting with camptocormia that only emerged during the "off" state of PD. The patient was treated with classical dopaminergic anti-Parkinson's therapy plus a new formulation of palmitoylethanolamide co-ultramicronized with luteolin (Lut) termed um-PEALut. We observed that the addition of um-PEALut to acute treatment with carbidopa/levodopa resulted in improved dyskinesia and reduced camptocormia. The patient continued treatment for four months, resulting in a complete resolution of leg and trunk dyskinesia and a marked reduction in the onset of camptocormia during the "off" states. CONCLUSION: um-PEALut shows potential as an efficacious adjuvant therapy for patients with PD receiving carbidopa/levodopa to treat both dyskinesia and camptocormia in acute and chronic fashion.
Authors: Marco Koch; Susanne Kreutz; Charlotte Böttger; Alexander Benz; Erik Maronde; Chalid Ghadban; Horst-Werner Korf; Faramarz Dehghani Journal: Neurotox Res Date: 2010-03-11 Impact factor: 3.911
Authors: Carlo Caltagirone; Carlo Cisari; Carlo Schievano; Rosanna Di Paola; Marika Cordaro; Giuseppe Bruschetta; Emanuela Esposito; Salvatore Cuzzocrea Journal: Transl Stroke Res Date: 2015-12-26 Impact factor: 6.829